Keynote Address: New approaches for treating dysregulated adaptive immunity
Jo Viney, PhD, Co-Founder, President, CEO, Seismic Therapeutic

Session I: Clinical development of IL-23 inhibitors: From mAb monotherapies to combo and novel orals
Co-Chairs: Heidi Feldser & Siquan Sun

  • Advancements in IL-23 in Health & Disease: from Research to Clinical Development of IL-23 Inhibitors
  • Molecular Differentiation of Anti-IL-23 Therapeutics
  • From the Laboratory to the Clinic: Anti-TNF and Anti-IL-23 Combination Therapy in Inflammatory Bowel Disease
  • First-in-Class Oral Peptide Systemically Targeting the IL-23 Pathway

Session II: New frontiers in systems immunology: how new technologies and AI can guide therapeutic discovery & development
Co-Chairs: Arpita Maiti and Dale Wright

  • Mapping and Navigating Biology and Chemistry at a Genome Scale
  • Targeting RNA with small molecules – Lessons from mapping the druggable transcriptome
  • Spatial Transcriptomics of Hidradenitis Suppurativa Tissue Reveals Disease Biology
  • Immune System Modeling to Drive Key Pharma R&D Decisions
    • Liza Aizman, Senior Director of Science Operations, CytoReason

Session III: Translational research and innovative technologies
Co-Chairs: Xiaofeng Yang and John Armstrong

  • Single cell RNA-Seq for inflammation research
  • Inflammation triggered tissue remodeling and novel therapeutics
  • Mass spectrometry based approaches to blood based marker detection for Oncology
  • A.I. for Drug Development in Immune-Mediated Inflammatory Disorders

Session IV: New Approaches to Treat Autoimmune Diseases by Promoting Tolerance
Co-Chairs: Lisa Schopf and Fridrik Karlsson

  • Ligand-non-competitive blocking of TNFRSFs for treatment of autoimmune diseases
  • Restoration of Immune Balance with Immune Checkpoint Modulation: A New Treatment Paradigm
    • Cailin Sibley, MD; Vice President Translational Medicine, AnaptysBio
  • (neo)Antigen-specific immunotherapy for autoimmune diabetes
    • James DiLisio, M.S., Graduate Student, Haskins lab, University of Colorado Anschutz Medical Campus
  • Open Panel Discussion: 30 minutes
    • Suggested topics for the panel discussion may include new antigen-specific tolerance promoting therapeutic vaccines, Treg-promoting cytokines, CAR-Tregs and checkpoint receptor agonists.

Session V: Selected Poster Abstracts
Co-Chairs: Sharlene Velichko and Caitlin Parello
Click HERE for all poster abstracts.

  • Neutralizing antibodies suggest C-C motif chemokine receptor-like 2 (CCRL2) ligand binding function is dispensable for neutrophil responses to CXCL8
  • Colitis Development in Germ-Free IL-10 Deficient Mice Inoculated with Murine FMT

Session VI: Early Discovery Strategies in Inflammation: Mechanisms, Targets and Approaches
Chair: Liwu Li

  • Innate immune memory dynamics and therapeutics
    • Liwu Li, PhD, Professor of Virginia Tech
  • Human Genetics Based Drug Discovery and Development
  • Trained immunity and inflammation enhancement
  • Drugging the Undruggable

Session VII: Meet the Professional Networking Session
Moderator: Lisa Marshall
Click HERE for Session Expectations & Additional Resources.

Session VIII: The RA Continuum: Discoveries, Care, and Patient Resilience
Co-Chairs: Heather Jones and Ana Biljan

Disease Area:
  1. Inhibitory signaling mechanisms in B cells: critical for B cell tolerance and potential therapeutic targets to treat autoimmune disease
  2. Patient Perspective
  3. Q & A

Session IX: Inflammation and Pain: New Science and New Treatment Strategies
Chair: Dirk Smith

  • Acute inflammation protects against the development of chronic pain
  • Dermal macrophages set pain sensitivity
  • B cell regulation of neuropathic pain
  • Q&A and roundtable

Session X: Emerging Therapeutic Strategies in Inflammation: New Drugs & Novel Clinical Approaches
Co-Chairs: Miguel Sanjuan and Xiao Hu

  • AG019 ActoBiotics as Monotherapy or in Combination with Teplizumab in Recent-Onset T1D Was Safe and Demonstrated Encouraging Metabolic and Immunological Effects
  • Multiple-Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of PRV-101, a Coxsackie Virus B (CVB) Vaccine, in Healthy Adult Subjects
    • Miguel Sanjuan, Senior VP Research & Early Development at Provention Bio a Sanofi Company
  • Identifying New IBD Drug Targets & Accompanying Patient Stratification Biomarkers from Large Multi-Modal Datasets